{"title":"减肥药研究结果带来希望，但仍需谨慎","authors":"Gary Enos","doi":"10.1002/adaw.34334","DOIUrl":null,"url":null,"abstract":"<p>Addiction researchers continue to preach caution amid a flurry of findings suggesting that popular weight-loss medications such as semaglutide could have important applications in treating substance use disorders (SUDs). The latest report found a decreased risk of alcohol use disorder-related hospitalization in patients who use semaglutide or liraglutide and its lead investigator is echoing the call for evidence from randomized trials to confirm conclusions drawn from observational studies.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 45","pages":"1-8"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Findings on weight-loss drugs offer hope, but caution needed\",\"authors\":\"Gary Enos\",\"doi\":\"10.1002/adaw.34334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Addiction researchers continue to preach caution amid a flurry of findings suggesting that popular weight-loss medications such as semaglutide could have important applications in treating substance use disorders (SUDs). The latest report found a decreased risk of alcohol use disorder-related hospitalization in patients who use semaglutide or liraglutide and its lead investigator is echoing the call for evidence from randomized trials to confirm conclusions drawn from observational studies.</p>\",\"PeriodicalId\":100073,\"journal\":{\"name\":\"Alcoholism & Drug Abuse Weekly\",\"volume\":\"36 45\",\"pages\":\"1-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcoholism & Drug Abuse Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcoholism & Drug Abuse Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Findings on weight-loss drugs offer hope, but caution needed
Addiction researchers continue to preach caution amid a flurry of findings suggesting that popular weight-loss medications such as semaglutide could have important applications in treating substance use disorders (SUDs). The latest report found a decreased risk of alcohol use disorder-related hospitalization in patients who use semaglutide or liraglutide and its lead investigator is echoing the call for evidence from randomized trials to confirm conclusions drawn from observational studies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
